102 related articles for article (PubMed ID: 3515364)
1. Ex vivo activated monocytes and adoptive immunotherapy trials in colon cancer patients.
Stevenson HC; Foon KA; Sugarbaker PH
Prog Clin Biol Res; 1986; 211():75-82. PubMed ID: 3515364
[No Abstract] [Full Text] [Related]
2. Fate of gamma-interferon-activated killer blood monocytes adoptively transferred into the abdominal cavity of patients with peritoneal carcinomatosis.
Stevenson HC; Keenan AM; Woodhouse C; Ottow RT; Miller P; Steller EP; Foon KA; Abrams PG; Beman J; Larson SM
Cancer Res; 1987 Nov; 47(22):6100-3. PubMed ID: 3117363
[TBL] [Abstract][Full Text] [Related]
3. Activation of tumoricidal properties in peripheral blood monocytes of patients with colorectal carcinoma.
Fidler IJ; Jessup JM; Fogler WE; Staerkel R; Mazumder A
Cancer Res; 1986 Feb; 46(2):994-8. PubMed ID: 3000591
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo models for monitoring the adoptive immunotherapeutic effects of recombinant gamma-interferon-activated human monocytes.
Edington HD; Stevenson HC; Sugarbaker PH
Curr Surg; 1987; 44(3):210-3. PubMed ID: 3109811
[No Abstract] [Full Text] [Related]
5. Involvement of effector cells in the treatment with endotoxins of peritoneal carcinomatosis induced by colon tumour cells.
Lagadec P; Jeannin JF; Pelletier H; Reisser D; Olsson NO
Anticancer Res; 1989; 9(2):421-5. PubMed ID: 2751266
[TBL] [Abstract][Full Text] [Related]
6. A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2.
Rosenberg SA; Lotze MT; Muul LM; Leitman S; Chang AE; Vetto JT; Seipp CA; Simpson C
Surgery; 1986 Aug; 100(2):262-72. PubMed ID: 3526604
[TBL] [Abstract][Full Text] [Related]
7. Novel immunotherapy for peritoneal dissemination of murine colon cancer with macrophage inflammatory protein-1beta mediated by a tumor-specific vector, HVJ cationic liposomes.
Miyata T; Yamamoto S; Sakamoto K; Morishita R; Kaneda Y
Cancer Gene Ther; 2001 Nov; 8(11):852-60. PubMed ID: 11773975
[TBL] [Abstract][Full Text] [Related]
8. Current cancer immunology.
Prog Exp Tumor Res; 1980; 25():1-295. PubMed ID: 7355241
[No Abstract] [Full Text] [Related]
9. IL-2 enhances standard IFNgamma/LPS activation of macrophage cytotoxicity to human ovarian carcinoma in vitro: a potential for adoptive cellular immunotherapy.
Han X; Wilbanks GD; Devaja O; Ruperelia V; Raju KS
Gynecol Oncol; 1999 Nov; 75(2):198-210. PubMed ID: 10525372
[TBL] [Abstract][Full Text] [Related]
10. New approaches to assessing and treating early-stage colon and rectal cancers: cooperative group strategies for assessing optimal approaches in early-stage disease.
Benson AB
Clin Cancer Res; 2007 Nov; 13(22 Pt 2):6913s-20s. PubMed ID: 18006800
[TBL] [Abstract][Full Text] [Related]
11. [Adjuvant treatment in surgery of colon and rectal cancer].
Fleischer I; Wainstein R; de Gibson AM
Acta Gastroenterol Latinoam; 1982; 12(2):189-93. PubMed ID: 6818807
[TBL] [Abstract][Full Text] [Related]
12. Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase i trial.
Krause SW; Gastpar R; Andreesen R; Gross C; Ullrich H; Thonigs G; Pfister K; Multhoff G
Clin Cancer Res; 2004 Jun; 10(11):3699-707. PubMed ID: 15173076
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant therapy for resectable rectal and colonic cancer.
Heriot AG; Kumar D
Br J Surg; 1998 Mar; 85(3):300-9. PubMed ID: 9529480
[TBL] [Abstract][Full Text] [Related]
14. Perspectives on interleukin-2 immunotherapy for colon cancer.
Chang AE
Gastroenterology; 1994 Dec; 107(6):1890-2. PubMed ID: 7958708
[No Abstract] [Full Text] [Related]
15. Adjuvant therapy in colorectal cancer.
Parshad R
Trop Gastroenterol; 1997; 18(4):139-44. PubMed ID: 9612092
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant therapy in high-risk colon cancer.
Bleiberg H
Semin Oncol; 2000 Oct; 27(5 Suppl 10):48-59. PubMed ID: 11049033
[No Abstract] [Full Text] [Related]
17. [Dynamics of cytotoxicity of blood mononuclear cells in patients with bladder cancer during endolymphatic immunotherapy with lymphokine- activated killer cells and recombinant interleukin-2].
Malakhova NV; Figurin KM; Fedorova NS; Kiselevskiĭ MV; Bykovskaia SN
Biull Eksp Biol Med; 1996 Feb; 121(2):188-91. PubMed ID: 9026128
[No Abstract] [Full Text] [Related]
18. New adjuvant therapy for colon cancer: justified hope or commercial hype.
Galanis E; Alberts SR; O'Connell MJ
Surg Oncol Clin N Am; 2000 Oct; 9(4):813-23; discussion 825-6. PubMed ID: 11008249
[TBL] [Abstract][Full Text] [Related]
19. [Gene therapy for colon cancer].
Suehiro Y; Hamanaka Y; Hinoda Y
Nihon Rinsho; 2005 Dec; 63 Suppl 12():533-6. PubMed ID: 16416848
[No Abstract] [Full Text] [Related]
20. Cellular immunotherapy with dendritic cells in cancer: current status.
Nencioni A; Brossart P
Stem Cells; 2004; 22(4):501-13. PubMed ID: 15277696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
